Related Experiment Video
Updated: Feb 10, 2026

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Fangrui Wu1, Gang Cheng1, Yuan Yao1
1Department of Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, United States.
Background:
R132H mutation of isocitrate dehydrogenase 1 (IDH1) is found in ~75% of low-grade gliomas and secondary glioblastomas as well as in several other types of cancer. More chemotypes of inhibitors of IDH1(R132H) are therefore needed.
Objective:
The study aimed to develop a new class of IDH1(R132H) inhibitors as potent antitumor agents.
Method:
A biochemical assay was developed to find inhibitors of IDH1(R132H) mutant enzyme. Chemical synthesis and structure-activity relationship studies were used to find compounds with improved potency. Antitumor activities of selected compounds were evaluated.
Results:
A series of aromatic sulfonamide compounds was found to be novel, potent inhibitors of IDH1(R132H) with Ki values as low as 0.6 µM. Structure-activity relationships of these compounds are discussed. Enzyme kinetics studies showed that one compound is a competitive inhibitor against the substrate α-KG and a non-competitive inhibitor against the cofactor NADPH. Several inhibitors were found to have no activity against wild-type IDH1, showing a high selectivity. Two potent inhibitors exhibited strong activity against proliferation of BT142 glioma cells with IDH1 R132H mutation, while these compounds did not significantly affect the growth of glioma cells without IDH1 mutation.
Conclusion:
This novel series of IDH1(R132H) inhibitors have potential to be further developed for the treatment of glioma with IDH1 mutation.
Insights
Novel aromatic sulfonamides effectively inhibit the R132H mutation in isocitrate dehydrogenase 1 (IDH1), showing potent antitumor activity against glioma cells with this specific mutation.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Oncology
Background:
- The R132H mutation in isocitrate dehydrogenase 1 (IDH1) is prevalent in gliomas and other cancers.
- There is a need for diverse chemical classes of IDH1(R132H) inhibitors.
Purpose of the Study:
- To develop a new class of potent IDH1(R132H) inhibitors.
- To explore their potential as antitumor agents.
Main Methods:
- Development of a biochemical assay for IDH1(R132H) inhibition.
- Chemical synthesis and structure-activity relationship (SAR) studies.
- Evaluation of antitumor activity in glioma cell lines.
Main Results:
- A novel series of aromatic sulfonamides were identified as potent IDH1(R132H) inhibitors (Ki as low as 0.6 µM).
- SAR studies guided compound optimization.
- Selected inhibitors demonstrated high selectivity for mutant IDH1 over wild-type IDH1.
- Two compounds potently inhibited proliferation of IDH1 R132H-mutated glioma cells without affecting wild-type cells.
Conclusions:
- The identified aromatic sulfonamides represent a promising new class of IDH1(R132H) inhibitors.
- These compounds hold potential for the development of novel glioma treatments targeting IDH1 mutations.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Cancers Originate from Somatic Mutations in a Single Cell
Viral Mutations
Feedback Inhibition
Mutation, Gene Flow, and Genetic Drift

